

FORGGITH PHARMACEUTICALS

Sales Performance




FORGGITH PHARMACEUTICALS

Marketing Performance







Volume Achieved vs Volume Target



Top Performing Product by Revenue and Volume achieved								
ProductName	Total Revenue ▼	Volume Achieved						
Ionclotide	\$165,614,153.00	262,463						
Tetratanyl	\$121,015,531.00	236,821						
Sumanazole	\$109,205,702.00	206,438						
Betanem	\$103,571,832.00	169,512						
Docstryl Rivacin	\$98,670,762.00	125,058						
Travoloride	\$96,419,980.00	122,828						
Propratecan	\$93,594,270.00	137,235						
Ketastadil	\$92,200,920.00	120,840						
Nevanide Actozide	\$92,048,067.00	119,079						

Performance of Sales Reps Compared to Targets

Name	Actual Revenue	Target Revenue	Target Revenue Achievement	Volume Achieved	Target Volume	Target Volume Achievement	Revenue YTD	Total Target YTD	
Abigail Thompson	\$929,427,257.00	\$712,012,896.00	23.39%	2,179,360	1,772,592	18.66%	\$237,921,641.00	\$204,298,164.00	
Jimmy Grey	\$928,946,974.00	\$582,276,732.00	37.32%	2,153,474	1,463,316	32.05%	\$196,603,611.00	\$167,065,812.00	
Sheila Stones	\$903,565,506.00	\$638,908,128.00	29.29%	2,252,562	1,529,244	32.11%	\$208,761,931.00	\$183,338,772.00	
Daniel Gates	\$895,102,799.00	\$588,161,220.00	34.29%	2,180,288	1,522,572	30.17%	\$239,479,087.00	\$168,769,404.00	
Anne Wu	\$864,742,861.00	\$776,594,688.00	10.19%	2,100,608	1,799,076	14.35%	\$219,688,398.00	\$222,793,224.00	
Morris Garcia	\$844,681,990.00	\$702,790,524.00	16.80%	2,119,503	1,720,944	18.80%	\$207,617,856.00	\$201,674,700.00	
Stella Given	\$840,996,176.00	\$505,221,504.00	39.93%	1,991,933	1,325,064	33.48%	\$257,895,110.00	\$144,988,800.00	
Jessica Smith	\$832,986,693.00	\$715,518,168.00	14.10%	2,019,806	1,769,328	12.40%	\$158,915,109.00	\$205,318,896.00	
Mary Gerrard	\$827,667,061.00	\$700,871,196.00	15.32%	1,984,219	1,587,852	19.98%	\$169,006,400.00	\$201,099,732.00	
Total	\$11,118,109,069.00	\$8,453,326,524.00	23.97%	27,004,449	20,505,144	24.07%	\$2,659,672,415.00	\$2,425,582,776.00	